KTTA Projected Dividend Yield
Pasithea Therapeutics Corp ( NASDAQ : KTTA )Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. Co. is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. 20 YEAR PERFORMANCE RESULTS |
KTTA Dividend History Detail KTTA Dividend News KTTA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |